Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VIS
|
|||
| Former ID |
DNCL002939
|
|||
| Drug Name |
AKB-9778
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Peripheral arterial disease [ICD-11: BD4Z; ICD-10: I73, I73.9; ICD-9: 443] | Phase 2 | [2] | ||
| Company |
Aerpio Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26N4O6S3
|
|||
| Canonical SMILES |
COC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4
|
|||
| InChI |
1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
|
|||
| InChIKey |
KWJDHELCGJFUHW-SFTDATJTSA-N
|
|||
| CAS Number |
CAS 1008510-37-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin 1 receptor (TEK) | Target Info | Activator | [1] |
| Protein tyrosine phosphatase beta (PTPRB) | Target Info | Modulator | [3] | |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | Wnt Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | |||
| SHP2 signaling | ||||
| Reactome | Tie2 Signaling | |||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | |||
| Cell surface interactions at the vascular wall | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02387788) Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO. U.S. National Institutes of Health. | |||
| REF 3 | Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.